Last reviewed · How we verify
NCT00002548
Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study
Phase 3 trial testing recombinant interferon alfa in Multiple Myeloma in 899 participants. Completed in 1 November 2006.
1 October 2003
Quick facts
| Lead sponsor | SWOG Cancer Research Network |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 899 |
| Start date | 1 January 1994 |
| Primary completion | 1 October 2003 |
| Estimated completion | 1 November 2006 |
| Sites | 34 locations across United States |
Drugs / interventions tested
- recombinant interferon alfa
- carmustine
- cyclophosphamide (cyclophosphamide) — full drug profile →
- dexamethasone (dexamethasone) — full drug profile →
- doxorubicin hydrochloride — full drug profile →
- melphalan
- prednisone (prednisone) — full drug profile →
- vincristine sulfate (Vincristine Sulfate) — full drug profile →
- allogeneic bone marrow transplantation
- autologous bone marrow transplantation
- peripheral blood stem cell transplantation
- radiation therapy
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
SWOG Cancer Research Network
Who can join
Adults 18 to 70, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
survival
Time frame: 3 years from randomization
Sponsor's own description
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of melphalan, total-body irradiation, and peripheral stem cell transplantation with that of combination chemotherapy in treating patients who have previously untreated multiple myeloma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, et al · · 2012 · cited 297× · PMID 22689675 · DOI 10.3324/haematol.2012.065698 -
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.
Redman MW, Goldman BH, LeBlanc M, Schott A, et al · · 2013 · cited 16× · PMID 23669424 · DOI 10.1158/1078-0432.ccr-12-2939
Verify or expand the search:
- PubMed search for NCT00002548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of recombinant interferon alfa
Trials testing the same drug.
- NCT00897520 — Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy · completed
- NCT00004088 — Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma · Phase 2 · completed
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other SWOG Cancer Research Network trials
Trials by the same sponsor.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
- NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
- NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00002548 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
- Last refreshed: 5 March 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing